9198B2FA-637D-44B2-B6E8-24B5681737AA
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 13.66622864651774
- age_years
- 35
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MITOTIC_SPINDLE+0.421
- TGF_BETA_SIGNALING+0.421
- G2M_CHECKPOINT+0.412
- WNT_BETA_CATENIN_SIGNALING+0.378
- PROTEIN_SECRETION+0.334
- E2F_TARGETS+0.333
- NOTCH_SIGNALING+0.332
- HEDGEHOG_SIGNALING+0.262
- MYC_TARGETS_V2+0.257
- MYC_TARGETS_V1+0.253
Top 10 suppressed
- KRAS_SIGNALING_DN-0.425
- MYOGENESIS-0.368
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.318
- PANCREAS_BETA_CELLS-0.304
- SPERMATOGENESIS-0.278
- COAGULATION-0.238
- ANGIOGENESIS-0.227
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.215
- OXIDATIVE_PHOSPHORYLATION-0.192
- HYPOXIA-0.186
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | D5E8379B-621C-4551-9B13-E63B1B068488 | — | — | 0.922 |
| 2 | 84778027-9C8E-4364-9069-70D8B86D6916 | — | — | 0.911 |
| 3 | SRR934870 | — | — | 0.909 |
| 4 | SRR934789 | — | — | 0.907 |
| 5 | 8D39DD37-3B56-4788-B256-D924EBF2BD21 | — | — | 0.900 |
| 6 | 2FA21196-17B0-4D16-BCA7-7E405CA2C1C5 | — | — | 0.887 |
| 7 | SRR934799 | — | — | 0.877 |
| 8 | 1F4B7E2E-E242-410A-AE78-8FC412D3C0A9 | — | — | 0.875 |
| 9 | 4A4E96B0-5AC6-4B7D-AB1C-F814C338589C | — | — | 0.873 |
| 10 | 9EE765BF-748F-41B9-926F-FFD0E8C079E3 | — | — | 0.873 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MITOTIC_SPINDLE | 0.421 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.421 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.412 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.378 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.334 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.333 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.332 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.262 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.257 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.253 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.244 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.207 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.185 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.178 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.135 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.116 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.095 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.093 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.081 | Inavolisib | — uncovered |
| PEROXISOME | 0.075 | Idelalisib | — uncovered |